Bacteroides acidifaciens enriched by KRAS mutation promotes colorectal tumorigenesis.

Bacteroides acidifaciens enrichment driven by KRAS mutation promotes colorectal tumorigenesis, correlating with poor prognosis in KRAS-mutant CRC patients.

• Why it matters: Understanding how host genetic mutations influence the tumor microbiome is crucial for developing targeted therapies, as this interplay may drive cancer progression and treatment resistance.
• What they did: The study analyzed intratumoral microbiomes from KRAS-mutant CRC patients and KRAS G12D mice, revealing KRAS-driven enrichment of B. acidifaciens, and used cell and mouse models to investigate its role and mechanisms.
• The result: B. acidifaciens enhances malignant traits in KRAS-mutant CRC via ARHGEF2 stabilization and KRAS pathway activation, suggesting targeting this microbiome component could mitigate KRAS-driven tumor growth.